Abstract: TH-PO689
Efficacy and Safety of Daprodustat for Treatment of Anemia in CKD: A Meta-Analysis
Session Information
- Anemia and Iron Metabolism
November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Anemia and Iron Metabolism
- 200 Anemia and Iron Metabolism
Authors
- Khor, Si Yuan, Michigan State University College of Human Medicine, East Lansing, Michigan, United States
- Alattal, Sara, Michigan State University College of Human Medicine, East Lansing, Michigan, United States
- Kamboj, Amira Sneha, Michigan State University College of Human Medicine, East Lansing, Michigan, United States
- Al-Abcha, Abdullah, Michigan State University College of Human Medicine, East Lansing, Michigan, United States
- Haddad, Issa R., Michigan State University College of Human Medicine, East Lansing, Michigan, United States
- Turk, Michael, Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
- Hernandez Garcilazo, Nora H., Michigan State University College of Human Medicine, East Lansing, Michigan, United States
- Radhakrishnan, Yeshwanter, Mayo Clinic, Rochester, Minnesota, United States
- Hassanein, Mohamed, University of Mississippi Medical Center, Jackson, Mississippi, United States
Background
Anemia is a well-known complication in chronic kidney disease (CKD). Current treatments for anemia in CKD include recombinant human erythropoietin (rhEPO) or its analogs. Daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor is a novel drug for treatment of anemia in CKD. We sought to review the efficacy and safety of daprodustat for treatment of anemia in non-dialysis dependent (NDD) and dialysis-dependent (DD) CKD patients.
Methods
We performed a systematic search using PubMed, Embase and Scopus until May 2022. Inclusion criteria included randomized controlled trials that reported the efficacy and safety of daprodustat compared to placebo or rhEPO in treating anemia patients with NDD or DD-CKD. Primary and secondary outcomes include change in hemoglobin (Hb) levels and associated adverse events (AEs), respectively. A random-effect model was utilized to calculate the mean difference and risk ratio with a 95% confidence interval.
Results
Eleven studies were included with a total of 8354 patients. The change in Hb levels were significantly higher in the daprodustat group compared to placebo for both DD (p=0.01) and NDD (p=0.002) patients with no significant difference in the incidence of AEs between the 2 groups (16.5% vs 7.4%, p=0.43; 19.1% vs 15.9%, p=0.73). There was no significant difference in change in Hb levels between daprodustat and rhEPO. The incidence of AEs was slightly higher in daprodustat group compared to rhEPO for NDD patients (p=0.02) with no significant difference in DD patients (p=0.78).
Conclusion
Our meta-analysis demonstrates that daprodustat was superior to placebo and non-inferior to rhEPO in treating anemia in CKD. The risk of AEs with daprodustat was slightly higher compared to rhEPO but was not observed when compared to placebo. Further clinical trials are required to validate the long-term efficacy and safety of daprodustat.